Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| CD8-positive, alpha-beta T cell | 6 studies | 22% ± 7% | |
| ciliated cell | 5 studies | 35% ± 7% | |
| regulatory T cell | 5 studies | 26% ± 12% | |
| basal cell | 3 studies | 27% ± 4% | |
| natural killer cell | 3 studies | 21% ± 3% | |
| abnormal cell | 3 studies | 49% ± 7% | |
| CD4-positive, alpha-beta T cell | 3 studies | 22% ± 1% | |
| effector CD8-positive, alpha-beta T cell | 3 studies | 30% ± 8% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| lung | 3 studies | 25% ± 5% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| esophagus | 92% | 173.11 | 1335 / 1445 | 52% | 27.76 | 96 / 183 |
| lung | 89% | 115.86 | 517 / 578 | 47% | 22.53 | 543 / 1155 |
| uterus | 46% | 37.37 | 79 / 170 | 88% | 120.95 | 403 / 459 |
| adrenal gland | 100% | 394.68 | 258 / 258 | 30% | 7.46 | 68 / 230 |
| ovary | 32% | 22.16 | 57 / 180 | 88% | 160.13 | 378 / 430 |
| bladder | 76% | 111.52 | 16 / 21 | 42% | 34.82 | 211 / 504 |
| intestine | 80% | 94.41 | 774 / 966 | 25% | 8.49 | 132 / 527 |
| skin | 58% | 246.94 | 1046 / 1809 | 45% | 21.86 | 211 / 472 |
| breast | 75% | 145.06 | 344 / 459 | 27% | 13.03 | 305 / 1118 |
| brain | 73% | 70.92 | 1920 / 2642 | 29% | 13.37 | 201 / 705 |
| spleen | 100% | 276.66 | 241 / 241 | 0% | 0 | 0 / 0 |
| stomach | 69% | 79.50 | 248 / 359 | 26% | 12.11 | 74 / 286 |
| prostate | 90% | 106.08 | 220 / 245 | 2% | 0.21 | 8 / 502 |
| tonsil | 0% | 0 | 0 / 0 | 89% | 108.90 | 40 / 45 |
| thymus | 72% | 61.29 | 468 / 653 | 13% | 2.56 | 80 / 605 |
| blood vessel | 83% | 157.27 | 1114 / 1335 | 0% | 0 | 0 / 0 |
| pancreas | 38% | 26.39 | 123 / 328 | 33% | 15.85 | 59 / 178 |
| adipose | 67% | 68.53 | 808 / 1204 | 0% | 0 | 0 / 0 |
| peripheral blood | 54% | 203.63 | 505 / 929 | 0% | 0 | 0 / 0 |
| liver | 11% | 8.01 | 25 / 226 | 31% | 7.66 | 125 / 406 |
| lymph node | 0% | 0 | 0 / 0 | 28% | 4.69 | 8 / 29 |
| eye | 0% | 0 | 0 / 0 | 25% | 4.34 | 20 / 80 |
| kidney | 18% | 12.37 | 16 / 89 | 7% | 1.68 | 60 / 901 |
| muscle | 11% | 9.07 | 92 / 803 | 0% | 0 | 0 / 0 |
| heart | 6% | 6.30 | 52 / 861 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
| GO_2000111 | Biological process | positive regulation of macrophage apoptotic process |
| GO_0016925 | Biological process | protein sumoylation |
| GO_0006919 | Biological process | activation of cysteine-type endopeptidase activity involved in apoptotic process |
| GO_0007265 | Biological process | Ras protein signal transduction |
| GO_0008285 | Biological process | negative regulation of cell population proliferation |
| GO_2000059 | Biological process | negative regulation of ubiquitin-dependent protein catabolic process |
| GO_0000209 | Biological process | protein polyubiquitination |
| GO_0048103 | Biological process | somatic stem cell division |
| GO_0000079 | Biological process | regulation of cyclin-dependent protein serine/threonine kinase activity |
| GO_0010628 | Biological process | positive regulation of gene expression |
| GO_0001953 | Biological process | negative regulation of cell-matrix adhesion |
| GO_2000045 | Biological process | regulation of G1/S transition of mitotic cell cycle |
| GO_0090399 | Biological process | replicative senescence |
| GO_0031648 | Biological process | protein destabilization |
| GO_0032088 | Biological process | negative regulation of NF-kappaB transcription factor activity |
| GO_0042326 | Biological process | negative regulation of phosphorylation |
| GO_0034393 | Biological process | positive regulation of smooth muscle cell apoptotic process |
| GO_2000435 | Biological process | negative regulation of protein neddylation |
| GO_0031647 | Biological process | regulation of protein stability |
| GO_1990000 | Biological process | amyloid fibril formation |
| GO_0008637 | Biological process | apoptotic mitochondrial changes |
| GO_0033235 | Biological process | positive regulation of protein sumoylation |
| GO_0045893 | Biological process | positive regulation of DNA-templated transcription |
| GO_0050821 | Biological process | protein stabilization |
| GO_0070534 | Biological process | protein K63-linked ubiquitination |
| GO_1904667 | Biological process | negative regulation of ubiquitin protein ligase activity |
| GO_1902510 | Biological process | regulation of apoptotic DNA fragmentation |
| GO_0090398 | Biological process | cellular senescence |
| GO_0033088 | Biological process | negative regulation of immature T cell proliferation in thymus |
| GO_0045736 | Biological process | negative regulation of cyclin-dependent protein serine/threonine kinase activity |
| GO_0051444 | Biological process | negative regulation of ubiquitin-protein transferase activity |
| GO_0043065 | Biological process | positive regulation of apoptotic process |
| GO_0006364 | Biological process | rRNA processing |
| GO_0045892 | Biological process | negative regulation of DNA-templated transcription |
| GO_0051726 | Biological process | regulation of cell cycle |
| GO_0030889 | Biological process | negative regulation of B cell proliferation |
| GO_0045944 | Biological process | positive regulation of transcription by RNA polymerase II |
| GO_0030308 | Biological process | negative regulation of cell growth |
| GO_0005730 | Cellular component | nucleolus |
| GO_0035985 | Cellular component | senescence-associated heterochromatin focus |
| GO_0005654 | Cellular component | nucleoplasm |
| GO_0005829 | Cellular component | cytosol |
| GO_0005759 | Cellular component | mitochondrial matrix |
| GO_0005737 | Cellular component | cytoplasm |
| GO_0005634 | Cellular component | nucleus |
| GO_0003677 | Molecular function | DNA binding |
| GO_0019789 | Molecular function | SUMO transferase activity |
| GO_1990948 | Molecular function | ubiquitin ligase inhibitor activity |
| GO_0055105 | Molecular function | ubiquitin-protein transferase inhibitor activity |
| GO_0019901 | Molecular function | protein kinase binding |
| GO_0061629 | Molecular function | RNA polymerase II-specific DNA-binding transcription factor binding |
| GO_0003723 | Molecular function | RNA binding |
| GO_0004861 | Molecular function | cyclin-dependent protein serine/threonine kinase inhibitor activity |
| GO_0097718 | Molecular function | disordered domain specific binding |
| GO_0005515 | Molecular function | protein binding |
| GO_0051059 | Molecular function | NF-kappaB binding |
| Gene name | CDKN2A |
| Protein name | p16 protein Truncated tumor suppressor protein P16 p16 Cyclin-dependent kinase inhibitor 2A (Cyclin-dependent kinase 4 inhibitor A) (CDK4I) (Multiple tumor suppressor 1) (MTS-1) (p16-INK4a) (p16-INK4) (p16INK4A) Cyclin-dependent kinase inhibitor 2A Cyclin dependent kinase inhibitor 2A Tumor suppressor ARF (Alternative reading frame) (ARF) (Cyclin-dependent kinase inhibitor 2A) (p14ARF) Alternative protein CDKN2A |
| Synonyms | CDKN2 MTS1 MLM |
| Description | FUNCTION: Acts as a negative regulator of the proliferation of normal cells by interacting strongly with CDK4 and CDK6. This inhibits their ability to interact with cyclins D and to phosphorylate the retinoblastoma protein. . FUNCTION: Capable of inducing cell cycle arrest in G1 and G2 phases. Acts as a tumor suppressor. Binds to MDM2 and blocks its nucleocytoplasmic shuttling by sequestering it in the nucleolus. This inhibits the oncogenic action of MDM2 by blocking MDM2-induced degradation of p53 and enhancing p53-dependent transactivation and apoptosis. Also induces G2 arrest and apoptosis in a p53-independent manner by preventing the activation of cyclin B1/CDC2 complexes. Binds to BCL6 and down-regulates BCL6-induced transcriptional repression. Binds to E2F1 and MYC and blocks their transcriptional activator activity but has no effect on MYC transcriptional repression. Binds to TOP1/TOPOI and stimulates its activity. This complex binds to rRNA gene promoters and may play a role in rRNA transcription and/or maturation. Interacts with NPM1/B23 and promotes its polyubiquitination and degradation, thus inhibiting rRNA processing. Plays a role in inhibiting ribosome biogenesis, perhaps by binding to the nucleolar localization sequence of transcription termination factor TTF1, and thereby preventing nucleolar localization of TTF1 (By similarity). Interacts with COMMD1 and promotes its 'Lys63'-linked polyubiquitination. Interacts with UBE2I/UBC9 and enhances sumoylation of a number of its binding partners including MDM2 and E2F1. Binds to HUWE1 and represses its ubiquitin ligase activity. May play a role in controlling cell proliferation and apoptosis during mammary gland development. .; FUNCTION: [Isoform smARF]: May be involved in regulation of autophagy and caspase-independent cell death; the short-lived mitochondrial isoform is stabilized by C1QBP. . |
| Accessions | Q8N726 Q208B5 A7LNE7 K7PML8 ENST00000579755.2 [Q8N726-1] ENST00000530628.2 [Q8N726-1] Q2MJK0 J3QRG6 ENST00000304494.10 [P42771-1] Q5ZEY9 ENST00000479692.2 ENST00000380151.3 [P42771-3] Q9UPB7 P42771 ENST00000497750.1 K7ES20 K7ENC6 ENST00000498124.1 [P42771-4] ENST00000579122.1 ENST00000498628.6 [P42771-2] D1LYX3 ENST00000578845.2 [P42771-2] ENST00000494262.5 [P42771-2] L8E941 |
